83 search results for: symposium

expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

10 min

Dermatology

Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.

expert video

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis

7 min

Dermatology

Dr. Saini provides a deep dive into the pathophysiology of type 2 inflammation in CSU.

expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

26 min

Type 2 Inflammation

Dr. Robert Bissonnette explains the role of type 2 inflammation in skin barrier dysfunction and how regulation of type 2 inflammation can normalize the skin barrier and potentially modify the disease with early intervention.

expert video

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

29 min

Dermatology

Review the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies.

expert video

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

1 min

Dermatology

Dr. Saini describes immune cells and mediators beyond mast cells that are also essential for helping to drive CSU pathology.

expert video

Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

56 min

Dermatology

Experts discuss the latest evidence on how type 2 inflammation drives skin barrier dysfunction, affects the skin microbiome, and contributes to neuroimmune dysregulation in AD.

expert video

Skin Dysbiosis in AD

17 min

Dermatology

Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.

expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

2 min

Dermatology

Dr. Saini summarises the potential role of type 2 cytokines in the pathogensis of CSU.

Infographic

The Burden of AD: More Than Skin Deep

5 min

Dermatology

Learn how the multidimensional, cumulative burdens of atopic dermatitis extend beyond the skin and across multiple organ systems, manifesting as atopic and non-atopic comorbidities. Even when an individual is performing well in spite of these burdens, they may still have significant life course impairment due to the cumulative impact of the disease.

expert video

What do we mean by disease control in AD?

3 min

Dermatology

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

expert video

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

5 min

Type 2 Inflammation

Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function

expert video

Pediatric Asthma Trajectory and Clinical Remission

4 min

Type 2 Inflammation

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region